All News

For endocrinologists, a cardiologist, a diabetes educator, and a room full of fellow health workers, the cost of doing nothing—not just to treat diabetes, but also to prevent it— is what feeds into the exorbitant cost of the disease, according to presentations and a panel at the inaugural meeting of the Institute for Value Based Medicine (IVBM) in Diabetes, an initiative of The American Journal of Managed Care®.

During the European Congress of Clinical Microbiology & Infectious Disease (ECCMID), being held in Amsterdam, the Netherlands, April 13-16, researchers are presenting findings that suggests the mode of delivery influences the development of gut microbiota in infants, regardless of a mother’s use of antibiotics, which could then affect infants’ respiratory health during his or her first year.

This week, the top managed care news included CDC clarifying its opioid guidelines for chronic pain; pharmacy benefit managers testifying before a Senate committee; Sanofi expanding its insulin savings program starting in June.

When antibiotics were discovered, they were considered a miracle. Decades of overuse have created a current public health crisis with a growing number of antibiotic-resistant bacteria. However, not all hope is lost in the fight against antibiotic resistance. There are programs in place to promote judicious use of antibiotics and policies and funding to help incentivize development of new antibiotics.

A recently published study looked to evaluate the effect of a single dose of nilotinib (Tasigna) in patients with PD. While nilotinib is FDA approved for the treatment of adult patients with chronic myeloid leukemia and not PD, the drug is able to penetrate the blood-brain barrier and reduce inflammation as well as lower levels of a toxic protein that prevents the brain from utilizing dopamine stored in vessels in areas of the brain that may control movement.

Researchers of a recently published study used preclinical behavioral models of migraine to determine that the application of calcitonin gene-related peptide (CGRP) to the dura mater, or the protective outer layer between the skull and the brain, in mice triggers pain responses only in females.

Rising consumerism, new competition, and payment models designed to keep patients out of acute care are forcing hospital-centric enterprises to rethink their delivery models. Organizations that excel in building integrated care delivery ecosystems and lasting consumer relationships based on a differentiated brand promise and superior outcomes will be the ones that find success.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo